Patents
Patents for G01N 33 - Investigating or analysing materials by specific methods not covered by groups (393,632)
09/2004
09/16/2004WO2004079254A1 Device for monitoring the flow of a fluid flowing through or from a conduit, such as a lubricant, and the monitoring method implemented by the device
09/16/2004WO2004079013A1 Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
09/16/2004WO2004079006A1 Method for identifying the function of a gene
09/16/2004WO2004078999A1 Identification of fetal dna and fetal cell markers in maternal plasma or serum
09/16/2004WO2004078998A1 Fluorescence polarization assay for determining binding of a test compound to pdhk (pyruvate dehydrogenase kinase)
09/16/2004WO2004078995A2 Methods of modulating and of identifying agents that modulate intracellular calcium
09/16/2004WO2004078986A1 Infectious flavivirus pseudo-particles containing functional prm and/or e proteins
09/16/2004WO2004078985A1 Animal model for the fast identification of pharmaceutical active compounds in vivo
09/16/2004WO2004078984A1 Animal model for the fast identification of pharmaceutical active compounds in vivo
09/16/2004WO2004078975A1 Novel protein and use thereof
09/16/2004WO2004078972A1 Chimeric receptors and method of screening ligands or inhibitors for the receptors
09/16/2004WO2004078969A1 Identification and utilization of chondroitin polymerization factor
09/16/2004WO2004078968A1 System for evaluating drug metabolism capacity and method of using the same
09/16/2004WO2004078960A1 Amylases producing an altered immunogenic response and methods of making and using the same
09/16/2004WO2004078948A2 METHOD TO IDENTIFY REGULATORS OF CELLULAR ACTIVATION USING Bcl10
09/16/2004WO2004078938A2 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
09/16/2004WO2004078934A2 Targeting site-2 protease (s2p) for the treatment of pancreatic cancer
09/16/2004WO2004078928A2 T cell regulation
09/16/2004WO2004078926A2 Immunologigal markers
09/16/2004WO2004078925A2 Methods and compositions for treating and preventing neurodegenerative diseases
09/16/2004WO2004078923A2 Pyk2 crystal structure and uses
09/16/2004WO2004078918A2 Materials and methods relating to therapy and diagnosis using targeting of cells that express dcal-hy polypeptides
09/16/2004WO2004078913A2 Methods
09/16/2004WO2004078909A2 Identification of antigen epitopes
09/16/2004WO2004078907A2 Streptococcus pyogenes antigens
09/16/2004WO2004078906A2 Method for producing a immobilised virus carrier and the use thereof
09/16/2004WO2004078778A2 PEPTIDES THAT SPECIFICALLY BIND HGF RECEPTOR (cMet) AND USES THEREOF
09/16/2004WO2004078775A2 Intracellular signaling-induced ret-independent gdnf receptor-effected morphological changes
09/16/2004WO2004078724A1 Method of labeling phosphorylated peptide, method of selective adsorption therefor, complex compound for use therein, process for producing the complex compound and starting compound of the complex compound
09/16/2004WO2004078594A2 Ligand/binding partner bio-labeling systems
09/16/2004WO2004078233A2 Cartridge having an integrated collection element for point of care system
09/16/2004WO2004078232A2 Collection device adapted to accept cartridge for point of care system
09/16/2004WO2004078208A1 MEDICINAL USE OF MIP-3α INHIBITOR AND METHOD OF SCREENING BRAIN/NERVE CELL PROTECTIVE AGENT
09/16/2004WO2004078204A1 Markers of blood barrier permeability and methods of using same
09/16/2004WO2004078195A1 Agent for converting intestinal cell into insulin-producing cell and remedy for diabetes
09/16/2004WO2004078175A2 Pharmaceutical preparations containing thiazolidinediones for the treatment or prevention of ip-10 mediated diseases
09/16/2004WO2004078146A2 Trans-membrane-antibody induced inhibition of apoptosis
09/16/2004WO2004078143A2 Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
09/16/2004WO2004078135A2 LIGANDS THAT BIND TO THE AMYLOID-β PRECURSOR PEPTIDE AND RELATED MOLECULES AND USES THEREOF
09/16/2004WO2004078131A2 Evaluating effects of exposure conditions on drug samples over time
09/16/2004WO2004078130A2 Posh interacting proteins and related methods
09/16/2004WO2004078123A2 Early prostate cancer antigens (epca), polynucleotide sequences encoding them, and their use
09/16/2004WO2004078035A2 Expression profiles for breast cancer and methods of use
09/16/2004WO2004077942A2 Inducible prostate cancer model
09/16/2004WO2004068104A3 Target activated microtransfer
09/16/2004WO2004064972A9 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
09/16/2004WO2004063719A3 Method to form a protein microarray system
09/16/2004WO2004063711A3 Use of adiponectin to diagnose and treat malignancy
09/16/2004WO2004062627A9 In vivo screening models for treatment of alzheimer's disease and other neurodegenerative disorders
09/16/2004WO2004055199A3 A biological sample storage device and method for biological sample contamination testing
09/16/2004WO2004053483A3 Multi-analyte reference solutions
09/16/2004WO2004050706A3 Regulatory t-cells
09/16/2004WO2004047762A3 Methods for treating cancer using porimin as a target
09/16/2004WO2004046376A3 Methods and kits for diagnosing and treating b-cell chronic lymphocytic leukemia (b-cll)
09/16/2004WO2004044582A3 Antibody- or neutrophil-mediated ozone generation
09/16/2004WO2004039489A3 Computer programs,workstations, systems and methods for microfluidic substrates in cell
09/16/2004WO2004027018A3 Inducible focal adhesion kinase cell assay
09/16/2004WO2004025255A3 Methods of assessing endothelial dysfunction using acute transient response following fat administration
09/16/2004WO2004022721A3 Quantification of gene expression
09/16/2004WO2004020081A3 Production of variable concentration fluid mixtures
09/16/2004WO2004013180A3 Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
09/16/2004WO2004011938B1 Method and device for screening molecules in cells
09/16/2004WO2004009791A3 Modulators of b-lymphocyte activation, myosin-1f compositions and methods of use
09/16/2004WO2004005540A3 Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
09/16/2004WO2003105666A3 Method of treating ischemia reperfusion injury using adenosine receptor antagonists
09/16/2004WO2003100012A3 Microarrays and method for running hybridization reaction for multiple samples on a single microarray
09/16/2004WO2003099778A3 Inhibitors of proteins from the rho-gef family
09/16/2004WO2003096974A3 ORIENTIA TSUTSUGAMUSHI TRUNCATED RECOMBINANT OUTER MENBRANE PROTEIN (r47) AND (r56) VACCINES DIAGNOSTICS AND THERAPEUTICS FOR SCRUB TYPHUS AND HIV INFECTION
09/16/2004WO2003096028A3 Methods and apparatus for identifying live eggs by detecting embryo heart rate and/or motion
09/16/2004WO2003091736A3 Quantitative analysis of a biological sample of unknown quantity
09/16/2004WO2003089901A3 Methods for preparing libraries of unique tags and related screening methods
09/16/2004WO2003083041A8 Cripto-specific antibodies
09/16/2004WO2003081239A3 Treating cancer
09/16/2004WO2003074128A3 Atomic structure of the hemalbumin complex and its use in designing therapeutic compounds
09/16/2004WO2003073822A3 Methods of diagnosing liver fibrosis
09/16/2004WO2003052048A3 Nucleic acid-associated proteins
09/16/2004WO2003046130A3 Methods for the identification of inhibitors of alpha-aminoadipate reductase and homocitrate synthase as antibiotics
09/16/2004WO2003040168A3 Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype
09/16/2004WO2003008436A3 Methods for the identification of peptidyl compounds interacting with extracellular target molecules
09/16/2004WO2002100827A3 Method for increasing the survival of dopamine secreting cells
09/16/2004WO2002099043A8 P5CRS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
09/16/2004WO2002092002A3 Screening, diagnostic and therapeutic methods relating to riz
09/16/2004US20040181363 Device for indicating the residual life of industrial products
09/16/2004US20040181351 Methods and devices for identifying related ions from chromatographic mass spectral datasets containing overlapping components
09/16/2004US20040181346 Multiple sensing system and device
09/16/2004US20040181344 Systems and methods for providing diagnostic services
09/16/2004US20040181343 Computer program products and systems for rapidly changing the solution environment around sensors
09/16/2004US20040181059 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents
09/16/2004US20040181047 33 human secreted proteins
09/16/2004US20040181043 comprising a label moiety attached to a linker for attachment to a ligand, and a photo-reactive group attached to the linker; can be used as a pre-probe for the preparation of bioprobes
09/16/2004US20040181033 Binding agents which inhibit myostatin
09/16/2004US20040180927 Inhibitors of cysteine protease
09/16/2004US20040180846 Connexin enhances chemotherapy-induced apoptiosis in human cancer cells inhibiting tumor cell proliferation
09/16/2004US20040180843 Treatment of helicobacter with isothocyanates
09/16/2004US20040180834 Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
09/16/2004US20040180829 Compounds and methods for regulating bacterial growth and pathogenesis
09/16/2004US20040180823 Peptides, peptidomimetics; promoting programmed cell death; neural regeneration
09/16/2004US20040180819 Characterization of a membrane estrogen receptor
09/16/2004US20040180817 Use of tumor necrosis factor alpha p75 receptor antagonist or endothelin receptor antagonist, converting enzyme inhibitor or neutralizing agent; reducting cerebral perfusion; method of identifying candidates
09/16/2004US20040180813 4-Amino acid functionalized-2-pyrophosphatyl-pyranes; direct assay, high throughput screening for enzyme inhibitors; N-acetylglucosaminyltransferase